Knockdown of GSK-3β or treatment with a GSK-3β inhibitors increased NFAT1 protein levels, but overexpression of GSK-3β decreased NFAT1 expression in RCC cells (Fig. 4L-O). Here, NFATC2 is linked to renal cell carcinoma.